Cell-Based Diagnostics: Technology, Applications, and Markets, 2nd Edition

Cell-Based Diagnostics: Technology, Applications, and Markets, 2nd Edition
CHAPTER ONE: EXECUTIVE SUMMARY
 
  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Market Trends

CHAPTER TWO: INTRODUCTION
 

  • Background: Cell-Based Testing in the 21st Century
  • The Cell, Inside and Out
  • The Status Quo and Huge Potential of Cell-Based Diagnostics
  • Point of View

CHAPTER THREE: MEDICAL TRENDS AND MARKET ISSUES IN THE COMMERCIALIZATION OF CELL BASED DIAGNOSTICS
 

  • Background
  • The Molecular Revolution, New Testing Opportunities
  • Reimbursement and Commercialization of Novel Tests
  • Regulatory Affairs
  • Worldwide Opportunities for Cell-Based Tests
  • Drug Discovery

CHAPTER FOUR: TECHNOLOGICAL TRENDS THAT ENABLE THE FUTURE OF CELL-BASED DIAGNOSTICS
 

  • Background
  • New Assay Designs
  • The In Vitro/In Vivo Mix
  • Personalized Medicine, Drug Selection, and Cell-Based Assays
  • Rare Cell Event Testing
  • Cancer Cells: Stem Cell Cousins
  • Miniaturization and Multiplexed Biological Assays
  • Cell Marker Development
  • Histology Automation
  • Cell Culture

CHAPTER FIVE: TECHNOLOGY PLATFORMS AT THE FOREFRONT OF CELL-BASED ASSAYS
 

  • Background
  • Hematology Analyzers
  • Flow Cytometry
  • Microscopy and Image-Based Platforms
  • Laser Capture Microdissection and Tissue Microarrays
  • In Situ Hybridization
  • Molecular Techniques

CHAPTER SIX: MARKET ANALYSIS
 

  • Background
  • Cell-Based Diagnostics and IVD Markets
  • The Market for Cell Assays in Cancer Management
  • The Market for Cell Assays in Hematology
  • The Market for Cell Assays in Histopathology/Cytology
    • The Future of the Pap Smear & HPV Testing
    • IHC/ISH and Digital Cytometry
  • The Market for Cell Assays in Microbiology/Virology
  • The Market for Cell Assays in Blood Product Safety
  • The Market for Cell Assays in Tissue Transplant Management
  • The Market for Cell Assays in Prenatal Testing

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
 

  • Conclusion
    • Implication
  • Conclusion
    • Implication
  • Conclusion
    • Implication
  • Conclusion
    • Implication
  • Conclusion
    • Implication

CHAPTER EIGHT: COMPANY PROFILES
 

  • Abbott Diagnostics
  • Accelr8 Technology Corporation
  • Accuri Cytometers
  • Acolyte Biomedica
  • Advanced Analytical Technologies Inc. (AATI)
  • AdvanDx, Inc.
  • Advalytix AG
  • Agendia B.V.
  • Almac Diagnostics (formerly ArraDx)
  • Amnis Corporation
  • Aperio Technologies, Inc.
  • Applied Imaging Corp./Genetix
  • Asuragen, Inc.
  • AviaraDx (formerly Arcturus Biosciences)
  • AVIVA Biosciences Corporation
  • Becton Dickinson & Company
  • Beckman Coulter, Inc.
  • Biocept, Inc.
  • BioGenex Laboratories, Inc.
  • Biomoda, Inc.
  • BioMosaics
  • BIOVIEW, Inc.
  • Bruker Daltonics
  • Cancer Genetics, Inc.
  • Celera
  • Celerus Diagnostics
  • CellaVision AB
  • Cellestis Ltd
  • Clarient Inc. (formerly ChromaVision)
  • Compucyte Corporation
  • Cylex Incorporated
  • CytoCore, Inc. (formerly Molecular Diagnostics, Inc.)
  • Cytyc Corporation
  • Dako A/S
  • DiaGenic ASA
  • Diagnostic Hybrids, Inc. (DHI)
  • Diamics, Inc.
  • Digene Corporation
  • eGene Inc.
  • Exagen Diagnostics, Inc.
  • Genomic Health
  • Greiner Bio-One International AG
  • Guava Technologies, Inc.
  • GW Medical Technologies, LLC
  • Gynecor
  • Hemosystem SA
  • HistoRx, Inc,
  • iCyt Visionary Bioscience
  • Ikonisys Inc.
  • Immunicon Corporation
  • InterGenetics
  • IntraCellular Diagnostics, Inc.
  • Invirion Diagnostics, LLC
  • Invitrogen Corporation
  • IPSOGEN
  • IRIS International, Inc.
  • MDS/Molecular Devices Corporation
  • Medion Diagnostics AG
  • Micro Imaging Technology (MIT)
  • Microgen Bioproducts
  • Micronics, Inc.
  • Milestone Medical
  • Modern Technology Corp.
  • MonoGen
  • Monogram Biosciences Inc. (formerly Virologic, Inc.)
  • MTM Laboratories AG
  • Nalge Nunc International Corporation
  • NorChip
  • Nuvera Biosciences
  • One Cell Systems, Inc.
  • Orpegen Pharma
  • Partec GmbH
  • Pathwork Diagnostics (formerly Predicant Biosciences)
  • Perceptronix Medical Inc.
  • PerkinElmer, Inc.
  • PointCare Technologies, Inc.
  • Progenika Biopharma S.A.
  • QBC Diagnostics Inc.
  • QuantomiX Ltd.
  • Rational Therapeutics
  • Ravgen
  • Sakura Finetek USA Inc.
  • Sequenom Inc.
  • Siemens Medical Solutions Diagnostics
  • Signature Genomic Laboratories LLC
  • Source MDx
  • Sysmex Corporation
  • Targeted Diagnostics & Therapeutics, Inc. (TDT)
  • Tripath Imaging, Inc.
  • Ventana Medical Systems. Inc.
  • Verax Biomedical Inc.
  • Veridex, LLC
  • Vision BioSystems Ltd/Danaher Corp.
  • Vitatex Inc.
  • WaveSense LLC
  • XDx, Inc
  • Xytos Inc.
  • Zila Inc.

Appendix: Selected Cell-Based Tests and Technologies
 

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
 

  • Table 1-1: Worldwide Cell Diagnostics Product Sales by Type 2006-2011

MEDICAL TRENDS AND MARKET ISSUES IN THE COMMERCIALIZATION OF CELL BASED DIAGNOSTICS
 

  • Table 3-1: Selected Cell-Based Molecular Tests
  • Table 3-2: Selected Commercial Cell-Based Molecular Tests
  • Table 3-3: Selected Cell-Based Tests Used in Drug Discovery

CHAPTER FOUR: TECHNOLOGICAL TRENDS THAT ENABLE THE FUTURE OF CELL-BASED DIAGNOSTICS
 

  • Table 4-1: Selected Tests and Cell Diagnostics Technology Crossovers
  • Table 4-2: Selected Cell-Based Lateral Flow Tests
  • Table 4-3: Selected Cell-Based Pharmacodiagnostic Tests
  • Table 4-4: Selected Rare Cell Event Tests
  • Table 4-5: Selected Cell Culture Tests

CHAPTER FIVE: TECHNOLOGY PLATFORMS AT THE FOREFRONT OF CELL-BASED ASSAYS
 

  • Table 5-1: Selected New Hematology Analyzer Tests, 1990s—2007
  • Table 5-2: Selected New Immunohematology Research Projects
  • Table 5-3: Revenue History of Leading Companies in Flow Cytometry 2001-2006
  • Table 5-4: Selected Flow Cytometry Applications
  • Table 5-5: Selected Flow Cytometry Product Companies
  • Table 5-6: Selected Microscopy and Image Analysis Product Companies
  • Table 5-7: Cytometry Imaging Market Revenues by Competitor 2006
  • Table 5-8: Selected LCM Systems on the Market, 2007
  • Table 5-9: Major Molecular Markers for Tissue Staining
  • Table 5-10: Selected In Situ Hybridization Histopathology Tests
  • Table 5-11: Selected Cell-Based Molecular Tests
  • Table 5-12: Selected DNA Sample Preparation Companies

CHAPTER SIX: MARKET ANALYSIS
 

  • Table 6-1: Selected Acquisitions and Collaborations in Cell Diagnostics
  • Table 6-2: Worldwide Cell Diagnostics Product Sales by Testing Area (Hematology, Histology/Cytology [without Pap], Flow Cytometry, DNA Microarrays, Pap, Protein Microarrays, Prenatal Testing, Tissue Typing, Tissue Microarrays, Microbiology/Virology, Rare Cell Event Detection, Blood Safety) 2006-2011
  • Table 6-3: Selected IVD Cancer Markers
  • Table 6-4: Worldwide Market for Cell Diagnostics for Cancer by Testing Area (Histology/Cytology [without Pap], Flow Cytometry, Pap, Tissue Microarrays, DNA Microarrays, Protein Microarrays, Rare Cell Event Detection, In Situ Hybridization, Immunohistochemical Staining) 2006
  • Table 6-5: Selected New Hematology Analyzer Tests, 1990s-2007
  • Table 6-6: Revenue History of the Top 5 Hematology Vendors 2001-2006
  • Table 6-7: Selected POC CBC Systems
  • Table 6-8: Worldwide Histology/Cytology Sales by Type (Traditional Non-Pap, Pap, IHC, ISH, Image Cytometry, Tissue Microarrays) 2006-2011